doi: 10.1128/AAC.32.9.1443.
Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime
Affiliations
- PMID: 3143306
- PMCID: PMC175888
- DOI: 10.1128/AAC.32.9.1443
Item in Clipboard
Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime
Antimicrob Agents Chemother.
1988 Sep.
Abstract
The selection frequencies of cefepime (BMY 28142), ceftazidime, and cefotaxime resistance among Pseudomonas aeruginosa strains were determined. Cefepime-resistant mutants were not selected by cefepime (frequency, less than 10(-11)). Ceftazidime- and cefotaxime-resistant mutants were isolated at frequencies of 10(-5) to 10(-10) and were often cross-resistant. However, cefepime resistance among ceftazidime- and cefotaxime-resistant mutants was rare. Selected mutants resistant to cefepime constitutively produced 40- to 450-fold more beta-lactamase than did the parent strain.
Similar articles
-
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498. Antimicrob Agents Chemother. 1989. PMID: 2499250 Free PMC article.
-
[The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].Cas Lek Cesk. 1997 Mar 12;136(5):154-6. Cas Lek Cesk. 1997. PMID: 9221190 Slovak.
-
Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):917-9. doi: 10.1007/BF01963783. Eur J Clin Microbiol Infect Dis. 1989. PMID: 2512141
-
Cefepime: overview of activity in vitro and in vivo.J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. doi: 10.1093/jac/32.suppl_b.87. J Antimicrob Chemother. 1993. PMID: 8150771 Review.
-
Cefepime: a review of its use in the management of hospitalized patients with pneumonia.Am J Respir Med. 2003;2(1):75-107. doi: 10.1007/BF03256641. Am J Respir Med. 2003. PMID: 14720024 Review.
Cited by
-
Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.Antimicrob Agents Chemother. 1991 Nov;35(11):2371-4. doi: 10.1128/AAC.35.11.2371. Antimicrob Agents Chemother. 1991. PMID: 1804010 Free PMC article. Clinical Trial.
-
Future directions in antimicrobial chemotherapy.Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545. Pharm Weekbl Sci. 1992. PMID: 1437505 Review.
-
Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.Antimicrob Agents Chemother. 1991 Apr;35(4):783-4. doi: 10.1128/AAC.35.4.783. Antimicrob Agents Chemother. 1991. PMID: 1906264 Free PMC article.
-
Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.J Antibiot (Tokyo). 2016 Dec;69(12):879-884. doi: 10.1038/ja.2016.45. Epub 2016 May 18. J Antibiot (Tokyo). 2016. PMID: 27189122 Free PMC article.
-
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.Antimicrob Agents Chemother. 1989 Apr;33(4):498-502. doi: 10.1128/AAC.33.4.498. Antimicrob Agents Chemother. 1989. PMID: 2499250 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
